MedPath
HSA Approval

NOTRIXUM 50 INJECTION 50MG/5ML

SIN16945P

NOTRIXUM 50 INJECTION 50MG/5ML

NOTRIXUM 50 INJECTION 50MG/5ML

February 7, 2024

GOLDPLUS UNIVERSAL PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGOLDPLUS UNIVERSAL PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

INTRAVENOUS

Medical Information

M03AC04

atracurium

Manufacturer Information

GOLDPLUS UNIVERSAL PTE LTD

PT. Novell Pharmaceutical Laboratories

Active Ingredients

Atracurium Besilate

50mg/5ml

Atracurium besylate

Documents

Package Inserts

Notrixum 50 Injection_PI.pdf

Approved: February 7, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NOTRIXUM 50 INJECTION 50MG/5ML - HSA Approval | MedPath